Abbott Laboratories (ABT) insider trading
Insider activity, historical context and SEC filings · data through Nov 20, 2026
Some insider buying ($4.4M), but sales were much larger ($47.9M) over the same 12 months.
Past insider buys here: 3 of 5 beat the S&P 500 over the next 90 days. See each one ↓
Label: Mixed: buying, heavier selling · based on open-market trades (codes P and S), last 12 months. Not a rating or advice.- Next earnings expected around Jan 26, 2027 (estimate from past release dates). Insiders usually trade in the weeks after results; past reactions ↓
Sale Mary K. Moreland, President sold 3,500 shares at $116.00 ($406K).
- Trade date
- Nov 5, 2026
- Disclosed to the SEC
- Nov 6, 2026
- Type
- Sale (code S)
Read the original SEC filing ↗All ABT insider trades ↓
Insiders have two business days to report a trade to the SEC, so filings (and our alerts) always come after the trade, never in real time.
ABT insider transactions (Form 4)
Open-market purchases and sales. 44 grants, option exercises and tax withholdings are not shown.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Nov 6SEC | Mary K. MorelandPresident | Sell | 3,500100,791 held (−3%) | $116.00 | $406K | -10.2% | — |
| Sep 3SEC | John A. McCoy Jr.President | Sell | 2724,549 held (−0%) | $109.54 | $3K | -4.9% | — |
| Aug 27SEC | Robert B. FordCEO, Chair | Sell | 218,535486,758 held (−31%) | $115.57 | $25.3M | -9.9% | — |
| Aug 27SEC | Robert B. FordCEO, Chair | Sell | 180,297306,461 held (−37%) | $116.19 | $20.9M | -10.3% | — |
| Aug 13SEC | Louis H. MorronePresident | Sell | 5,85070,724 held (−8%) | $109.83 | $643K | -5.2% | — |
| Jun 18SEC | John G. StrattonDirectorFirst buy | Buy | 2,00023,319 held (+9%) | $86.82 | $174K | +20.0% | — |
| Apr 28SEC | Daniel J. StarksDirectorPast buys 1/2 beat S&P | Buy | 10,0006,751,103 held (+0%) | $92.65 | $927K | +12.4% | 35 |
| Apr 27SEC | Philip P. BoudreauCFOFirst buyNew position | Buy | 2,200new position | $91.50 | $201K | +13.8% | — |
| Mar 3SEC | Louis H. MorronePresident | Sell | 1,14476,843 held (−1%) | $115.58 | $132K | -9.9% | — |
| Mar 3SEC | Daniel Gesua Sive SalvadoriPresident | Sell | 885146,377 held (−1%) | $115.58 | $102K | -9.9% | — |
| Mar 3SEC | Eric ShroffPresident | Sell | 70939,164 held (−2%) | $115.58 | $82K | -9.9% | — |
| Mar 3SEC | Mary K. MorelandPresident | Sell | 613104,291 held (−1%) | $115.58 | $71K | -9.9% | — |
| Mar 3SEC | John A. McCoy Jr.President | Sell | 58524,628 held (−2%) | $115.58 | $68K | -9.9% | — |
| Mar 3SEC | Elizabeth C. CushmanEvp, Gc And Secretary | Sell | 26338,573 held (−1%) | $115.58 | $30K | -9.9% | — |
| Feb 6SEC | Daniel J. StarksDirectorFirst buyPast buys 1/2 beat S&P | Buy | 5,0336,738,817 held (+0%) | $108.33 | $545K | -3.8% | 35 |
| Feb 6SEC | Daniel J. StarksDirectorFirst buyPast buys 1/2 beat S&P | Buy | 4,9676,733,784 held (+0%) | $109.14 | $542K | -4.6% | 35 |
| Jan 26SEC | Robert B. FordCEO, ChairFirst buy | Buy | 18,800216,203 held (+10%) | $107.13 | $2.0M | -2.8% | — |
| Nov 25SEC | Eric ShroffPresident | Sell | 1,58630,384 held (−5%) | $128.02 | $203K | -18.6% | — |
Similar past setups: not applicable. There aren't enough comparable past cases for ABT's latest buying to report odds. When insiders buy, this section shows how 6,290 similar past buys did over 90 days. How we calculate this →
Play with ABT in the Research Lab
Pre-set to ABT's latest insider buy of $10K or more (Jun 18, 2026: John G. Stratton, $174K). Tap to change anything.
Quick backtest: did buys like this beat the market?
Tap a setting to see how 6,290 past insider buys did.
Share price and insider trades
Abbott Laboratories insider trading at a glance (Nov 20, 2026): in the past 12 months, 4 insiders bought $4.4M and 7 sold $47.9M of ABT stock on the open market, including a cluster buy that began Apr 23, 2026; P/E 31.5 vs. a sector median of 25.0.
By InsiderPrint Research Desk · Updated · Sources: SEC EDGAR Form 4 filings, FINRA short-sale volume · How we calculate this
ABT insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | $406K | 1 |
| Q3 2026 | — | 0 | $46.9M | 4 |
| Q2 2026 | $1.3M | 3 | — | 0 |
| Q1 2026 | $3.1M | 3 | $485K | 6 |
| Q4 2025 | — | 0 | $203K | 1 |
Valuation, profit and volume
Source: SEC filings, as of Nov 16, 2026. Volume and paper profit use daily closing prices.
Summary
Over the past 12 months, 4 Abbott Laboratories insiders reported open-market purchases totaling $4.4M, while 7 insiders reported sales totaling $47.9M. The most recent cluster buy began on Apr 23, 2026, when 3 insiders bought a combined $1.3M. Among insiders with enough purchase history to measure, Daniel J. Starks (Director) has the highest Insider Score at 35. 0 of 12 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
ABT earnings: how the stock reacted
Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.
| Release | 15 days before | Insiders, 30 days before | Reaction (2 days) | Next 30 days |
|---|---|---|---|---|
| Oct 21, 2026 | +3.0% | None | +0.1%S&P -0.7% | pending |
| Jul 16, 2026 | -0.9% | None | +12.8%S&P -1.5% | +10.5% |
| Apr 16, 2026 | -0.5% | None | -4.7%S&P +1.5% | -12.7% |
| Jan 22, 2026 | -5.0% | None | -11.0%S&P +0.6% | +4.5% |
| Oct 15, 2025 | +0.1% | None | -3.8%S&P -0.2% | +2.3% |
| Jul 17, 2025 | -2.9% | None | -6.1%S&P +0.5% | +6.5% |
| Apr 16, 2025 | -4.4% | None | +3.8%S&P -2.1% | +2.9% |
| Jan 22, 2025 | +3.9% | None | +5.5%S&P +1.1% | +9.5% |
Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.
ABT short selling
Daily short-sale volume as a share of trading volume (FINRA), with the 20-day average.
This is short volume from off-exchange trades, not short interest. It includes market makers' routine hedging, so 40–50% is normal; what stands out is a ratio well above the stock's own average. Insiders buying while shorts pile in →
Members of Congress who traded ABT
From STOCK Act disclosures. Reported up to 45 days after the trade, in dollar ranges.
| Member | Trade | Traded | Reported | Since trade |
|---|---|---|---|---|
| Alan ArmstrongSenate | Sold $15,001 - $50,000 | Mar 27, 2026 | Jul 21, 2026 | +1.5% |
What happened after ABT insiders bought
Each open-market purchase, measured from the day the filing became public, next to the S&P 500 over the same days. Losses included; "pending" means the days haven't passed yet.
| Filed | Insider | Bought | 7 days | 30 days | 90 days |
|---|---|---|---|---|---|
| Jun 18, 2026 | John G. StrattonDirector | $174K | +5.5%+7.1% vs S&P | +15.8%+16.4% vs S&P | +15.9%+14.9% vs S&P |
| Apr 28, 2026 | Daniel J. StarksDirector | $927K | -7.1%-8.8% vs S&P | -8.1%-14.1% vs S&P | +12.1%+8.0% vs S&P |
| Apr 27, 2026 | Philip P. BoudreauCFO | $201K | -5.7%-6.1% vs S&P | -7.7%-12.6% vs S&P | +13.4%+9.8% vs S&P |
| Feb 6, 2026 | Daniel J. StarksDirector | $1.1M | +1.7%+3.0% vs S&P | +1.6%+3.4% vs S&P | -21.0%-27.2% vs S&P |
| Jan 26, 2026 | Robert B. FordCEO, Chair | $2.0M | +0.6%+0.2% vs S&P | +5.5%+5.4% vs S&P | -14.1%-17.7% vs S&P |
Insiders at Abbott Laboratories
| Insider | Bought | Sold | Last filing | Past buys beat S&P | Score |
|---|---|---|---|---|---|
| Robert B. FordCEO, Chair | $2.0M | $46.2M | Aug 27, 2026 | 0 of 1 | — |
| Daniel J. StarksDirector | $2.0M | — | Apr 28, 2026 | 1 of 2 | 35 |
| Louis H. MorronePresident | — | $775K | Aug 13, 2026 | — | — |
| Philip P. BoudreauCFO | $201K | — | Sep 3, 2026 | 1 of 1 | — |
| John G. StrattonDirector | $174K | — | Jun 18, 2026 | 1 of 1 | — |
| Mary K. MorelandPresident | — | $477K | Nov 6, 2026 | — | — |
| Eric ShroffPresident | — | $285K | Mar 3, 2026 | — | — |
| Daniel Gesua Sive SalvadoriPresident | — | $102K | Mar 3, 2026 | — | — |
| John A. McCoy Jr.President | — | $71K | Sep 3, 2026 | — | — |
| Elizabeth C. CushmanEvp, Gc And Secretary | — | $30K | Jun 29, 2026 | — | — |
| Kevin T. ConroyDirector | — | — | Sep 25, 2026 | — | — |
| Nancy McKinstryDirector | — | — | Apr 28, 2026 | — | — |
| Michael O'GradyDirector | — | — | Apr 28, 2026 | — | — |
| Sally E. BlountDirector | — | — | Apr 28, 2026 | — | — |
| Michael F. RomanDirector | — | — | Apr 28, 2026 | — | — |
| Michelle KumbierDirector | — | — | Apr 28, 2026 | 0 of 1 | — |
| Claire Babineaux-FontenotDirector | — | — | Apr 28, 2026 | — | — |
| Darren W. McDewDirector | — | — | Apr 28, 2026 | — | — |
| Patricia Paola GonzalezDirector | — | — | Apr 28, 2026 | — | — |
| Nita AhujaDirector | — | — | Apr 28, 2026 | — | — |
| Jacob A. OrvillePresident | — | — | Mar 25, 2026 | — | — |
| Lisa D. EarnhardtPresident | — | — | Mar 3, 2026 | — | — |
| Christopher J. ScogginsPresident | — | — | Mar 3, 2026 | — | — |
Board links: companies that share insiders with ABT
Directors and executives who filed Form 4s for ABT and another company in the last 12 months.
- ACNAccenture Nancy McKinstry Director here · Director at ACN · latest filing Nov 17, 2026
- ADPAutomatic Data Processing Nancy McKinstry Director here · Director at ADP · latest filing Nov 12, 2026
- ALGNAlign Technology Kevin T. Conroy Director here · Director at ALGN · latest filing Sep 25, 2026
- GDGeneral Dynamics John G. Stratton Director here · Director at GD · latest filing Sep 18, 2026
- GEGE Aerospace Darren W. McDew Director here · Director at GE · latest filing May 7, 2026
- MDLZMondelez International Nancy McKinstry Director here · Director at MDLZ · latest filing May 21, 2026
- NTRSNorthern Trust Michael O'Grady Director here · CEO, Chair at NTRS · latest filing Nov 5, 2026
- TDYTeledyne Technologies Michelle Kumbier Director here · Director at TDY · latest filing Apr 28, 2026
Insider activity at other Health Care companies
Same sector, ranked by insider buying in the last 90 days.
ABT stock: common questions
Are Abbott Laboratories insiders buying ABT stock?
In the past 12 months, 4 insiders reported open-market purchases of ABT worth $4.4M. The latest was Director John G Stratton bought $174K of ABT at $86.82 — first open-market purchase in our records.
Are Abbott Laboratories insiders selling ABT stock?
7 insiders reported sales worth $47.9M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is ABT's P/E ratio?
ABT trades at about 31.5 times trailing earnings, compared with a median of 25.0 for the Health Care sector.
What is ABT's 52-week range?
Over the past year ABT has traded between $81.98 and $126.55. It last closed at $104.17 on Nov 20, 2026.